In response to the duplication of data on consistency evaluation of some generic drugs reported by the media, on January 24, 2025, the Data Management Office of the Drug Evaluation Center of the National Medical Products Administration issued a "Correction Statement" stating that it was caused by editing errors and has been corrected.

Earlier, according to the First Financial News, there was news online recently that the similarity of multiple bioavailability data of the consistency evaluation of generic drugs by the National Medical Products Administration has aroused concern. The reporter checked the website of the Drug Evaluation Center of the National Medical Products Administration and found that there were indeed two generic drugs with exactly the same bioequivalence data when searching for "Rosuvastatin Calcium Tablets" and "Trimetazidine Hydrochloride Tablets".

The "Correction Note" stated that recently, the center received reports from relevant media and companies that there were duplicate data on some varieties disclosed on the website of the Drug Evaluation Center of the National Medical Products Administration.

The center immediately verified the data of the relevant varieties. "After verification, the above problems were caused by editing errors when the relevant product information was disclosed in 2019 and 2021. Our center has corrected the erroneous information on the center's website as soon as possible." The Drug Review Center of the National Drug Administration said.

The Drug Review Center of the National Drug Administration also stated that the center deeply apologizes for the mistakes made in its work and will strengthen the review of public information in the future to avoid similar problems from happening again.

Source: https://finance.eastmoney.com/